Uncategorized
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX</a>--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company entered into an employment agreement that provided for the grant of an inducement award outside the Company’s 2014 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted a stock option to purchase up